.22 mg semaglutide may 22 On February 21, 2025, the FDA announced that semaglutide, the active ingredient in These highlights do not include

When the medication stops, the biological pressures that caused weight gain in the first place reassert themselves

A medication that appears stronger in one headline may not be the best option for a specific patient

[1] [2] It works by mimicking the incretin hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways

Understanding the difference between microdose exposure and full therapeutic dosing helps clarify why low-dose experiences may not match the outcomes reported in trial data